Approval of Roche/Genentech’s Gazyvaro Set to Reshape the EU5 Lupus Nephritis Treatment Landscape, According to Spherix Global Insights
Strong physician readiness, high efficacy expectations, and anticipated displacement of off-label rituximab position Gazyvaro for rapid adoption across Europe EXTON, PA, December 11, 2025 — Following this week’s European Commission approval of Roche/Genentech’s Gazyvaro (obinutuzumab) for the treatment of lupus nephritis (LN), Spherix Global Insights’ latest RealTime Dynamix™: Lupus Nephritis (EU) study indicates that the […]
First Look at Roche/Genentech’s Gazyva Shows Strong Early Enthusiasm in Lupus Nephritis Launch, According to Spherix Global Insights
One-month post-launch, Gazyva’s perceived degree of advance exceeds benchmarks achieved by GSK’s Benlysta and Aurinia’s Lupkynis at comparable post-launch time points. EXTON, Pa., November 19, 2025 – Spherix Global Insights has released the first wave of Launch Dynamix™: Gazyva in Lupus Nephritis, providing the earliest independent read on the commercial introduction of Gazyva® (obinutuzumab, Genentech/Roche). […]
UCB’s Bimzelx and AbbVie’s Rinvoq Lead in EU5 Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondyloarthritis Growth
New insights from Spherix Global Insights reveal strong rheumatologist anticipation for next-generation oral and multi-pathway innovations, including Sotyktu, icotrokinra, and sonelokimab. EXTON, PA, November 13, 2025 – The 2025 Market Dynamix™: Psoriatic Arthritis and Ankylosing Spondylitis/Non-Radiographic Axial Spondyloarthritis (EU5) studies from Spherix Global Insights reveal a rapidly evolving treatment landscape, as rheumatologists expand use of […]
Novel Pipeline Activity Signals Hope in Systemic Sclerosis, as Rheumatologists Anticipate First Real Therapeutic Advances in Years
Familiarity with AstraZeneca’s Saphnelo and enthusiasm for next-generation biologics signal increasing optimism, though CAR T-cell therapy divides opinion amid safety and access concerns, according to Spherix Global Insights EXTON, PA, November 6, 2025 – According to the latest Market Dynamix™: Systemic Sclerosis (US) 2025 study from Spherix Global Insights, the treatment landscape for systemic sclerosis […]
Sjögren’s Disease Remains an Underdiagnosed and Underguided Condition, Creating an Opening for Manufacturers to Shape the Future of Care, According to Spherix Global Insights
With multiple late-stage assets advancing, manufacturers have a near-term opportunity to drive much-needed disease education and shape therapeutic direction. EXTON, PA, October 16, 2025 – Sjögren’s Disease (SjD) continues to present significant diagnostic and therapeutic challenges within rheumatology, according to Spherix Global Insights’ Market Dynamix™: Sjögren’s Disease (US) 2025 report. Despite growing awareness and expanding […]
Priovant’s Brepocitinib Poised to Address Steroid-Sparing Gap in Dermatomyositis as Rheumatologists Anticipate 2026 Launch
Physician sentiment captured in Spherix Global Insights’ research highlights high expectations for dual TYK2/JAK1 inhibition, with continued unmet needs across the broader IIM spectrum. EXTON, PA, October 10, 2025 – Rheumatologists are eagerly anticipating the potential approval of brepocitinib, Priovant Therapeutics’ dual TYK2/JAK1 inhibitor, as a near-term advance for dermatomyositis (DM). According to Spherix Global […]
US Rheumatologists View Cell Therapy as a Potential Game Changer, with Systemic Sclerosis Emerging as the Most Compelling Indication, According to Spherix Global Insights
New research reveals cautious optimism as physicians weigh transformative potential against safety, access, and the enduring role of biologics and advanced systemics across rheumatic conditions. EXTON, PA, October 6, 2025 – Cell therapy may represent a new frontier in the treatment of autoimmune diseases, with the majority of US rheumatologists reporting highly favorable impressions of […]
As Roche/Genentech’s Obinutuzumab (Gazyva) Nears FDA Decision, Spherix Global Insights White Paper Reveals Keys to Successful Lupus Product Launches
The white paper illustrates how recent lupus launches, including Lupkynis (Aurinia), Benlysta (GSK), and Saphnelo (AstraZeneca), showcase the critical role of strategic differentiation and targeted education in driving future uptake. Exton, PA, October 2, 2025 – Spherix Global Insights has released a new white paper, Navigating the Evolving SLE/Lupus Nephritis Landscape: Keys to Successful Product […]
AbbVie’s Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists
Spherix Global Insights finds majority of specialists expect Rinvoq’s uptake to accelerate, with potential implications branching to the polymyalgia rheumatica landscape. EXTON, PA, September 25, 2025 – Rheumatologists report high satisfaction with AbbVie’s Rinvoq (upadacitinib) following its recent approval in giant cell arteritis (GCA), with the majority citing anticipated efficacy, steroid-sparing benefits, and convenient oral […]
US Rheumatologists Point to Difficult-to-Treat populations, Oral Delivery, and Novel Mechanisms as the Key Drivers of Future RA Treatment Evolution, According to Spherix Global Insights
TNF biosimilars continue to expand, underscoring the tension between payer-driven cost pressures and pipeline-driven opportunity. EXTON, PA, August 25, 2025 – According to the latest findings from Spherix Global Insights’ Market Dynamix™: Rheumatoid Arthritis (US) 2025, the most notable near-term disruption in the RA market stems from continued TNF biosimilar adoption at the expense of […]
